Merck says some patents for its top-selling cancer drug, Keytruda, may be extended through 2029.

Merck on Tuesday revealed a lower-than-expected outlook for 2026 as the drugmaker aims to remake its business before its ...

Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this ...

Armed with what CEO Robert Davis called the “broadest and widest pipeline we’ve had in years,” Merck is preparing for its ...

Merck recorded higher revenue in its fourth quarter, but expects earnings growth to slow as it ramps up acquisitions.

Global pharmaceutical company Merck (NYSE:MRK) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 5% year on ...

Merck (MRK) ’s stock surged by 41% in the last six months, driven not only by a modest revenue increase but also by a ...

In its 2025 full year and fourth-quarter earnings call, Merck executives touted the merits of recent deals and what CEO ...

Merck will report its earnings on Tuesday, offering insights into how its agreement to lower the price of its diabetes drug ...

Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open. Wall Street expects earnings of $2.01 per ...

Merck reported revenue for the fourth quarter was $16.4 billion, an increase of 5% over the fourth quarter of 2024. For the ...